Apollon Formularies Plc - Total Voting Rights PR Newswire

30 June 2022

Apollon Formularies Plc

("Apollon" or the "Company")

Total Voting Rights

In accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, the Company hereby announces that it has 752,725,356 ordinary shares of no par value each in issue, each share carrying the right to one vote.

This figure of 752,725,356 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

The directors of the Company accept responsibility for the contents of this announcement.

-ENDS-

For further information please contact:

Apollon Formularies 

Tel:    +44 771 198 0221

Stene Jacobs    stene@apollon.org.uk

Peterhouse Capital Limited (Corporate Adviser)  

Tel:    +44 207 220 9795

Guy Miller      gm@peterhousecapital.com

BlytheRay (Financial PR/IR-London)   

Tel:    +44 207 138 3204

Tim Blythe/Megan Ray    apollon@blytheray.com

About Apollon and Apollon Jamaica

Apollon Formularies plc is an international medical cannabis company headquartered in the United Kingdom. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica. Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to cultivate, perform research and development, process, and sell medical cannabis therapeutic products that include legal medical cannabis to treat various illnesses under medical supervision. Apollon and Apollon Jamaica are parties to a Commitment Agreement whereby Apollon is entitled to 95% of Apollon Jamaica's Net Profits, and per a Stock Pledge Agreement that includes Stephen D. Barnhill, M.D., Apollon is to be assigned the entire 49% equity interest of Apollon Jamaica held by Dr. Barnhill, which is the maximum interest in a medical cannabis company allowed to be held by a non-Jamaican, upon the CLA approving the assignment.